CoronaVac / Sinovac, Bio Farma Indonesia - LARVOL DELTA

Immunogenicity and safety to SARS-Cov-2 vaccination in patients with systemic vasculitis. (PubMed, Front Immunol) - "ChAdOx1 nCoV-19 (AstraZeneca/Oxford) (n=36) and CoronaVac (Sinovac) (n=25) were primarily the most common vaccines, while BNT162b2 (Pfizer-BioNTech) was usually the booster vaccine...Different SARS-CoV-2 vaccines demonstrated immunogenicity and clinical effectiveness in systemic vasculitis. The three-dose schedule was safe without increasing relapse risk."

Journal • ANCA Vasculitis • Infectious Disease • Novel Coronavirus Disease • Rare Diseases • Respiratory Diseases • Rheumatology • Vasculitis

Impact of obesity on COVID-19 CoronaVac and ChAdOx1-S vaccine efficacy. (PubMed, BMC Infect Dis) - No abstract available

Journal • Genetic Disorders • Infectious Disease • Novel Coronavirus Disease • Obesity

Learning from the omicron BA.4/5 dominance: Strategies for future vaccination preparedness. (PubMed, Vaccine) - "This study provides evidence-based principles for future pandemic vaccination strategies. Platform-switching heterologous boosting (from inactivated vaccines to mRNA vaccines) offers meaningful advantages for inactivated vaccine recipients, bivalent vaccines provide substantial additional protection, and vaccination-first approaches consistently outperform infection-first scenarios. These findings support proactive vaccination policies over reliance on infection-acquired immunity and inform rapid response strategies for future pandemic threats."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Primary and Booster COVID-19 Vaccination in Patients with Sjögren's Disease: Data from the Longitudinal SAFER Cohort Study. (PubMed, Vaccines (Basel)) - "COVID-19 vaccination in patients with SjD was safe and induced high anti-spike antibody titers and seropositivity. Heterologous boosting, particularly with BNT162b2, demonstrated superior immunogenicity. No association was found between vaccination and SjD disease flares or worsening activity."

Journal • Immunology • Infectious Disease • Novel Coronavirus Disease • Sjogren's Syndrome

Comparison of the immunogenicity and safety among COVID-19 vaccines ChadOx-1, CoronaVac and BNT162b2 in systemic lupus erythematosus (SLE) patients: a prospective cohort. (PubMed, Adv Rheumatol) - "After two doses, the three COVID-19 vaccine platforms induced a significant increase in antibody titers against SARS-CoV-2. Patients who received BNT162b2 exhibited a higher serological response compared to the other vaccines. All three vaccine platforms demonstrated a favorable safety profile, with no serious ESAVI or worsening of disease activity."

Journal • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Musculoskeletal Pain • Novel Coronavirus Disease • Pain • Respiratory Diseases • Rheumatology • Systemic Lupus Erythematosus

T and B cell responses following primary COVID-19 vaccination with CoronaVac and two heterologous BNT162b2 booster doses. (PubMed, mSphere) - "These results demonstrate that CD4+ T cells induced by the second heterologous BNT162b2 booster play a key role in protection against SARS-CoV-2 infection and progression to severe disease. This study suggests the need for the future consideration of repeated emergency vaccine-boosting strategies in response to emerging viral infections."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD4 • CD8 • IFNG

COVID-19 breakthrough infections during the circulation of Delta and Omicron variants in Tirana, Albania, April 2021-March 2022. (PubMed, PLoS One) - "Incidence of COVID-19 breakthrough infection was significantly higher during the Omicron period and among younger individuals in Tirana. The substantially elevated risk associated with Omicron variant breakthrough infection and the decline in infection protection after a 5-month period, warrants close monitoring and rapid adaptation of vaccination strategies, including promoting booster vaccination to reduce breakthrough infections in the future."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Impact of SARS-CoV-2 Vaccination on Disease Activity and Severity of COVID-19 Infection in Patients with Systemic Lupus Erythematosus: A Multicenter Cohort Study. (PubMed, Vaccines (Basel)) - "Vaccination against SARS-CoV-2 demonstrated a favorable safety profile in patients with SLE, with a low frequency of serious adverse events. While analysis of disease activity revealed variations across vaccine platforms, most notably an increased proportion of moderate to high disease activity among those receiving ChAdOx-1 compared with CoronaVac and BNT162b2, the overall occurrence of COVID-19 during follow-up was limited to mild cases, with no severe outcomes. These findings highlight that, despite potential risks of disease exacerbation, the clear protection against severe COVID-19 supports vaccination as a beneficial strategy for this immunocompromised population."

Journal • Critical care • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Lupus • Novel Coronavirus Disease • Pain • Respiratory Diseases • Systemic Lupus Erythematosus

Neutralization and Anti-S Antibody Titers in SARS-CoV-2 Boosted Adults in Mexico: A Comparison Across Five Vaccine Types. (PubMed, Int J Microbiol) - "We observed that the highest anti-protein S GMTs were in the group that received a heterologous booster with BNT162b2, AZD1222, Ad5-nCoV, or CoronaVac; the group without a booster showed the lowest GMTs...Boosters increased GMTs for all people, independently of their primary vaccine scheme. Yet, our findings suggest that a heterologous booster produced higher titers against SARS-CoV-2 protein S. Efforts should be made to reach people who received AZD1222 and Ad5-nCoV as their primary scheme and did not get boosted, as neutralization in those groups was particularly low."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • PROS1

Immunogenicity of fractional and standard dose COVID-19 vaccine boosters among healthy adults in Indonesia: twenty four month follow-up from a randomised controlled trial. (PubMed, Nat Commun) - "This observational follow-up study of a double blind randomised controlled parallel group trial evaluates long-term immunogenicity, safety and breakthrough infections to 24 months after booster doses (fractional or standard Pfizer BNT162b2, fractional or standard AstraZeneca ChAdOx1, and standard dose CoronaVac) following CoronaVac and AstraZeneca primary series in healthy adults in Indonesia...Funding: Coalition for Epidemic Preparedness Innovations (CEPI). Trial registration: ina-registry.org , INA-GO0HLGB."

Clinical • Journal • Infectious Disease • Novel Coronavirus Disease

Public Health in the Headlines: A Study of Media Behavior on Discourses on Vaccination During COVID-19. (PubMed, Vaccines (Basel)) - "The study highlighted the potential importance of newspapers in disseminating information about vaccines during the pandemic, underscoring the need for regional health strategies to increase vaccination coverage."

Journal • Infectious Disease • Mental Retardation • Novel Coronavirus Disease

Antibody Responses to SARS-CoV-2 and Common HCoVs in Hemodialysis Patients and Transplant Recipients: Data from the Dominican Republic. (PubMed, Vaccines (Basel)) - "mRNA vaccination (BNT162b2) elicited stronger and more durable SARS-CoV-2 anti-S IgG responses than the inactivated CoronaVac vaccine, especially in immunocompetent individuals...MLMM identified key immunological and clinical predictors of antibody responses, emphasizing the critical role of host immune history. These findings highlight a constrained but meaningful role for HCoV cross-reactivity in SARS-CoV-2 immunity and vaccine responsiveness, underscore the need for infection markers unaffected by vaccination, and support development of broadly protective pan-coronavirus vaccines and tailored strategies for at-risk populations."

Journal • Infectious Disease • Novel Coronavirus Disease • Renal Disease • Respiratory Diseases • Transplantation

Toxic epidermal necrolysis: clinical aspects, treatment, complications and follow-up (EADV 2025) - "She received azathioprine, prednisone, cyclosporine, immunoglobulin...Case 5: A 41-year-old male patient had NET SCORTEN 3, 7 days after starting allopurinol... TEN is a rare and serious drug-induced disease with a high rate of mortality and complications. Although it is a medical emergency, there is still no effective and well-defined specific treatment. Lack of knowledge and delayed diagnosis are the main reasons for poor outcomes."

Clinical • Acute Kidney Injury • Cardiovascular • Chronic Obstructive Pulmonary Disease • Dengue Fever • Hemophagocytic lymphohistiocytosis • Immunology • Infectious Disease • Nephrology • Pulmonary Disease • Pulmonary Embolism • Renal Disease • Respiratory Diseases • Septic Shock • Steven-Johnson Syndrome • Tuberculosis

Safety and immunogenicity of SpiN-Tec, a T-cell based RBD-Nucleocapsid chimeric vaccine for COVID-19. (PubMed, Vaccine) - "Thirty-six healthy adults aged 18-54, previously vaccinated with two doses of CoronaVac™ (Sinovac) and a booster with the Comirnaty™ Bivalent BA.4/BA.5 (Pfizer-BioNTech), were randomized to receive either SpiN-Tec (20 μg, 60 μg, or 100 μg) or CoviShield™(AstraZeneca)...Importantly, SpiN-Tec induced robust IFN-γ production up to 270 days, particularly by CD4+ effector memory T cells, indicating a durable immune response memory. These results indicate the potential of SpiN-Tec as a viable COVID-19 booster vaccine."

Journal • Infectious Disease • Novel Coronavirus Disease • CD4 • IFNG

Impact of obstructive sleep apnea severity and treatment on COVID-19 vaccine-induced immune responses. (PubMed, J Thorac Dis) - "This study examines the effects of OSA on immune responses following the third dose of the inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine (CoronaVac or BBIBP-CorV)...These findings highlight a severity-dependent impairment of vaccine-induced immune responses in untreated OSA participants, with evidence that PAP treatment may enhance vaccine efficacy. This study emphasizes the need to consider OSA severity and treatment when optimizing vaccination strategies for this population."

Journal • Infectious Disease • Novel Coronavirus Disease • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Disorder

A High-Throughput Broad Neutralizing Antibody Assay for Detecting SARS-CoV-2 Variant Immunity in Population. (PubMed, ACS Infect Dis) - "Notably, the levels of NAbs against most of the SARS-CoV-2 variants are much lower in the decreased immunity of HIV patients (CD4+ 500 cells/μL), indicating that maintenance of the immune system is crucial for NAb production. Altogether, our high-throughput proteomics platform represents a powerful tool for the detection of bNAbs in the population and may inform the development of more effective COVID-19 vaccines and vaccination strategies in the future."

Journal • Human Immunodeficiency Virus • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD4

Epidemiological patterns of SARS-CoV-2 reinfections in Espírito Santo, Brazil: A population-based analysis using integrated surveillance and vaccination data. (PubMed, PLoS One) - "This study shows that the cumulative frequency of reinfections increased over the study period, reaching up to ~10% under the most inclusive definition, while remaining modest under the strictest criteria. These findings reinforce the importance of continued genomic surveillance, timely booster campaigns, and targeted interventions in high-risk environments. The integration of multiple data sources and the use of variable reinfection definitions allowed for a nuanced analysis, offering valuable insights to inform public health planning in Brazil and similar contexts."

Journal • Retrospective data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

The resident gut microbiome modulates the effect of synbiotics on the immunogenicity after SARS-COV-2 vaccination in elderly and diabetes patients. (PubMed, NPJ Biofilms Microbiomes) - "Importantly, SIM01 strain engraftment assessed by StrainPhlAn (A metagenomic strain-level population genomics tool) was associated with a higher fold change of three bifidobacterial species and could be predicted based on the baseline gut microbiome. Therefore, the resident gut microbiome affected the SIM01 engraftment, which was associated with the immunogenicity of SARS-CoV-2 BNT162b2 vaccines."

Journal • Diabetes • Infectious Disease • Metabolic Disorders • Novel Coronavirus Disease • Respiratory Diseases

Longitudinal dynamics of immune responses after mRNA and inactivated COVID-19 vaccination, boosters, and breakthrough infections in Malaysia. (PubMed, Vaccine) - "During the COVID-19 pandemic, Malaysia adopted heterologous vaccine booster strategies using BNT162b2 (Pfizer), CoronaVac (Sinovac) and ChAdOx1 nCoV-19 (AstraZeneca) due to vaccine shortages...In individuals infected two years after booster vaccination, T cell responses increased in healthy participants but declined in KTRs despite strong antibody responses, suggesting immunosuppressive therapy may impair T cell activation. These findings highlight the need for comprehensive immune assessments to guide preventive strategies, especially for immunocompromised populations."

Journal • Infectious Disease • Novel Coronavirus Disease • Transplantation

Polymorphism in IFNλ Can Impact the Immune/Inflammatory Response to COVID-19 Vaccination in Older CMV-Seropositive Adults. (PubMed, Vaccines (Basel)) - "CMV-seropositivity in older adults who had Allele-1 could lead to an unbalanced systemic inflammatory state, which may impair their antibody response to COVID-19 vaccination compared to other volunteer groups."

Journal • Cytomegalovirus Infection • Infectious Disease • Inflammation • Novel Coronavirus Disease • Respiratory Diseases • CD4 • CD8 • IFNB1 • IFNL3

Cross-neutralization effect of the third dose of inactivated COVID-19 vaccine against the SARS-CoV-2 variants. (PubMed, Expert Rev Vaccines) - "Among other variants, the GMFI against Omicron variants (BA.1, BA.4/5, BF.7) exceeded that for Beta and Delta, with the highest GMFI recorded for the BA.4/5 variant at 4.97 (95% CI: 3.08, 8.05). The necessity of the third booster dose lies in its ability to enhance the breadth of the immune response."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Clinical, epidemiological, and laboratory analysis of hospitalized and fatal COVID-19 cases in the first fully vaccinated municipality in Northeast Brazil. (PubMed, Rev Inst Med Trop Sao Paulo) - "Of these nine patients, 4 received anticoagulants and corticosteroids; 6, oxygen supplementation; 2, oseltamivir; and 3, empirical antibiotic for pneumonia. The mean interval between the last vaccine dose and hospitalization totaled 128 days (28-326; SD 137). These findings highlight incomplete vaccination, a prolonged interval since last doses, comorbidities, and advanced age as key factors associated with severe cases and deaths and emphasize the protective role of high vaccination coverage."

Journal • Cardiovascular • Cough • Diabetes • Hypertension • Infectious Disease • Metabolic Disorders • Novel Coronavirus Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases

Which type of vaccine is more beneficial for reducing the risk of deep vein thrombosis, CoronaVac, BNT162b2, or TURKOVAC? (PubMed, Sci Prog) - "Deep vein thrombosis was least common in patients who received only BNT162b2. Although the frequency of deep vein thrombosis was similar in the groups, we found that the lowest rate of deep vein thrombosis was in the group that received TURKOVAC after BNT162b2."

Journal • Cardiovascular • Hematological Disorders • Infectious Disease • Novel Coronavirus Disease • Thrombosis • Venous Thromboembolism

Age and primary vaccination schedule impact humoral and cellular immunity with an inactivated SARS-CoV-2 vaccine. (PubMed, iScience) - "The 0-14 schedule produced equivalent cellular and neutralizing antibody responses between age groups, albeit at lower levels than the 0-28 schedule. Our data indicate that primary vaccination schedules can influence the humoral immune responses and memory T cell distribution between age groups."

Journal • Cognitive Disorders • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD4 • CD8

Long-term efficacy and immune response of CoronaVac in Brazilian health care workers: Insights from PROFISCOV unblinded trial. (PubMed, Vaccine) - P3 | "IgG-N titres peaked in the 13th week and declined. The homologous booster enhanced significantly the immune response compared to the heterologous one (Pfizer)."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases